All News

Chimeric antigen receptor T-cell therapies, along with bispecific antibodies, have changed the treatment paradigm for patients with relapsed or refractory mantle cell lymphoma.

A new analysis based on two prospective trials helps clarify the roles of chemotherapy and radiotherapy.

Chronic kidney disease now affects more than 788 million adults globally, with rising prevalence, increasing mortality, and substantial contributions to cardiovascular deaths

A study identified 32 dysregulated cytokines and 5 key signaling hubs in idiopathic pulmonary fibrosis (IPF), mapping a complex network of profibrotic pathways that may serve as future therapeutic targets.

A combined assessment of genetic, serologic, and clinical factors may enhance early recognition of patients with RA who are most at risk for ILD.

Modern ibrutinib-based approaches substantially narrow the traditional survival gap observed in CLL.

Most US patients eligible for hepatitis B virus (HBV) treatment remain untreated, raising risks of liver disease and complications.

Baricitinib demonstrated significant reductions in disease activity in postmenopausal women with frontal fibrosing alopecia over 12 weeks.

The FDA expanded approvals for key medications, enhancing treatment options for atopic dermatitis, inflammatory bowel disease, type 2 diabetes, and more.

The FDA has approved pembrolizumab and enfortumab vedotin for muscle-invasive bladder cancer (MIBC), offering new hope for patients ineligible for cisplatin.

Individuals told their absolute risk of HIV had higher interest in pre-exposure prophylaxis (PrEP) compared with those told relative risk.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Scientists restored the CCNA2 gene in adult human heart cells, enabling them to divide and form new functional cardiomyocytes—advancing heart repair therapies.

Remibrutinib demonstrated rapid and sustained symptom relief for chronic spontaneous urticaria in a pooled analysis of REMIX-1 and REMIX-2.

Survivors of SJS/TEN face severe long-term physical and psychological effects, with major gaps in post-discharge care, support, and physician guidance.

The FDA approved selumetinib for adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas based on the KOMET trial.

Improving outcomes in chronic kidney disease relies on improving patient engagement.

Research shows a sharp rise in bisphenol-attributable metabolic disease since 2000, with annual costs exceeding $250 billion in North America.

Immune-boosting herbs were linked to lower autoantibody rates in patients before dermatomyositis onset, suggesting activation of alternative immune pathways.

The accelerated approval was based on a study that evaluated the efficacy in unresectable or metastatic nonsquamous NSCLC.

Previously treated patients with non–small cell lung cancer (NSCLC) saw durable results with andamertinib 240 mg.

A study links seborrheic dermatitis to multiple epithelial barrier diseases, supporting broader assessment for inflammation and barrier dysfunction.

Caregivers face communication challenges in coordinating patient care for older adults, highlighting the need for improved support and training.

Randomized clinical trials increasingly support mental health apps as scalable, cost-efficient tools for managing depression and anxiety.

Patients hospitalized for bronchiectasis exacerbations face higher mortality, longer stays, and greater costs than those with COPD or asthma.

An improvement in ophthalmological knowledge was seen compared with older large language models and ophthalmology trainees.

Rozanolixizumab shows promise in treating triple-seronegative myasthenia gravis, offering hope for patients with limited treatment options.

Long-term nitrogen dioxide exposure raises ovarian cancer risk, underscoring the need for stricter air quality measures.

Rachel A. Prusynski, DPT, PhD, discusses her study on how payment models affect home health care delivery and patient outcomes.

Semaglutide and tirzepatide led to the most weight loss across 22 trials, while liraglutide remains a cost-effective alternative as its patent expires.